Carmat announces that the first implantation of its Aeson artificial heart as part of the EFICAS clinical study was carried out during the last week of December 2022, by Professor André Vincentelli and his team at the Lille CHRU.

In addition to this institution, five other hospital centers (two in Paris, one in Rennes, one in Strasbourg and one in Lyon) are participating in this prospective study, which will involve a total of 52 patients eligible for transplantation in France.

The study will enable Carmat to gather additional data on the efficacy and safety of its artificial heart, as well as medico-economic data to support the device's value proposition and reimbursement, particularly in France.

Copyright (c) 2023 CercleFinance.com. All rights reserved.